Acute myocardial infarction

Summary

Acute myocardial infarction (MONDO:0004781) is a disease (an umbrella term covering 6 Mondo subtypes) with 2 cohort genes (17 GWAS associations across 8 studies) and 608 clinical trials. Top therapeutic interventions include clopidogrel, bisoprolol, and metoprolol.

At a glance

• Umbrella term: 6 Mondo subtypes
• Cohort genes: 2
• GWAS associations: 17
• ClinVar variants: 5
• Clinical trials: 608

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute myocardial infarction
Mondo ID	MONDO:0004781
EFO	EFO:0008583
DOID	DOID:9408
ICD-10-CM	I21.9
ICD-11	1334938734
NCIT	C35204
SNOMED CT	57054005
UMLS	C0155626
MedGen	57611
Is cancer (heuristic)	no

Also known as: acute myocardial infarction (disease) · myocardial infarction (disease), acute

Data availability: 5 ClinVar variants · 17 GWAS associations (8 studies).

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › myocardial disorder › myocardial infarction › acute myocardial infarction

Related subtypes (13): posteroinferior myocardial infarction, septal myocardial infarction, posterior myocardial infarction, apical myocardial infarction, subendocardial myocardial infarction, posterolateral myocardial infarction, inferolateral myocardial infarct, lateral myocardial infarction, silent myocardial infarction, anteroseptal myocardial infarction, myocardial stunning, anterolateral myocardial infarction, inferior myocardial infarction

Subtypes (6): acute subendocardial myocardial infarction, acute inferoposterior infarction, acute inferolateral myocardial infarction, acute anterolateral myocardial infarction, strictly posterior acute myocardial infarction, ST-elevation myocardial infarction

Genetics & variants

GWAS landscape

17 GWAS associations across 8 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr6:160540105	7e-32		?	0.42
chr19:44908822	3e-20		?	0.19
chr19:44908684	1e-17		?	0.12
chr2:202982094	6e-17		?	0.13
chr2:202901033	1e-16		?	0.13
chr15:90885060	3e-14		?	0.08
chr19:44892887	1e-12		?	0.1
chr1:222750009	2e-12		?	0.1
chr1:222629034	5e-11		?	0.09
chr2:85581614	7e-11		?	0.07
chr1:222629862	1e-10		?	0.09
chr2:85542588	2e-10		?	0.07
rs544366796	4e-10	SLC22A3	G	0.52
chr19:11100236	8e-10		?	0.1
chr1:55039974	1e-09		?	0.26
chr2:85553008	6e-09		?	0.07
chr13:110152462	7e-09		?	0.11

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90079973	Backman JD	2021	10,907	375,797	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083959	Backman JD	2021	10,907	375,797	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90043954	Jiang L	2021	8,528	447,820	A generalized linear mixed model association tool for biobank-scale data.
GCST90103349	Fitzgerald T	2022	5,541	165,216	CNest: A novel copy number association discovery method uncovers 862 new associations from 200,629 whole-exome sequence datasets in the UK Biobank.
GCST90079972	Backman JD	2021	5,398	381,223	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083958	Backman JD	2021	5,398	381,223	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90726897	Kim HI	2026	1,327	42,699	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90832963	Kim HI	2026	1,327	42,699	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	17

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	16

Functional consequences

Consequence	Count
unknown	16
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr6:160540105							7e-32	Tier 4: intronic/intergenic
chr19:44908822							3e-20	Tier 4: intronic/intergenic
chr19:44908684							1e-17	Tier 4: intronic/intergenic
chr2:202982094							6e-17	Tier 4: intronic/intergenic
chr2:202901033							1e-16	Tier 4: intronic/intergenic
chr15:90885060							3e-14	Tier 4: intronic/intergenic
chr19:44892887							1e-12	Tier 4: intronic/intergenic
chr1:222750009							2e-12	Tier 4: intronic/intergenic
chr1:222629034							5e-11	Tier 4: intronic/intergenic
chr2:85581614							7e-11	Tier 4: intronic/intergenic
chr1:222629862							1e-10	Tier 4: intronic/intergenic
chr2:85542588							2e-10	Tier 4: intronic/intergenic
rs544366796	6	160409518	C>G	0.01	intron_variant	SLC22A3	4e-10	Tier 4: intronic/intergenic
chr19:11100236							8e-10	Tier 4: intronic/intergenic
chr1:55039974							1e-09	Tier 4: intronic/intergenic
chr2:85553008							6e-09	Tier 4: intronic/intergenic
chr13:110152462							7e-09	Tier 4: intronic/intergenic

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

4 risk factor, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
375985	NM_002168.4(IDH2):c.516G>C (p.Arg172Ser)	IDH2	risk factor	no assertion criteria provided
375986	NM_002168.4(IDH2):c.515G>T (p.Arg172Met)	IDH2	risk factor	no assertion criteria provided
375987	NM_002168.4(IDH2):c.515G>A (p.Arg172Lys)	IDH2	risk factor	no assertion criteria provided
376438	NM_002168.4(IDH2):c.514A>T (p.Arg172Trp)	IDH2	risk factor	no assertion criteria provided
13454	NM_000371.4(TTR):c.386C>T (p.Ala129Val)	TTR	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 15 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TTR	Orphanet:597939	Euthyroid dysprealbuminemic hyperthyroxinemia
TTR	Orphanet:85447	ATTRV30M amyloidosis
TTR	Orphanet:85451	ATTRV122I amyloidosis
IDH2	Orphanet:163634	Maffucci syndrome
IDH2	Orphanet:251589	Anaplastic astrocytoma
IDH2	Orphanet:251598	Protoplasmic astrocytoma
IDH2	Orphanet:251601	Fibrillary astrocytoma
IDH2	Orphanet:251604	Gemistocytic astrocytoma
IDH2	Orphanet:251627	Oligodendroglioma
IDH2	Orphanet:251630	Anaplastic oligodendroglioma
IDH2	Orphanet:251656	Oligoastrocytoma
IDH2	Orphanet:251663	Anaplastic oligoastrocytoma
IDH2	Orphanet:296	Ollier disease
IDH2	Orphanet:79315	D-2-hydroxyglutaric aciduria
IDH2	Orphanet:86845	Acute myeloid leukaemia with myelodysplasia-related features

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TTR	HGNC:12405	ENSG00000118271	P02766	Transthyretin	clinvar
IDH2	HGNC:5383	ENSG00000182054	P48735	Isocitrate dehydrogenase [NADP], mitochondrial	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TTR	Transthyretin	Thyroid hormone-binding protein.
IDH2	Isocitrate dehydrogenase [NADP], mitochondrial	Plays a role in intermediary metabolism and energy production.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	1	6.0×	0.320
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TTR	Other/Unknown	no		Transthyretin/HIU_hydrolase, Transthyretin/HIU_hydrolase_d, Thyroxine_BS
IDH2	Enzyme (other)	yes	1.1.1.42	Isocitrate_DH_NADP, IsoCit/isopropylmalate_DH_CS, IsoPropMal-DH-like_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
choroid plexus epithelium	1
right lobe of liver	1
type B pancreatic cell	1
apex of heart	1
gastrocnemius	1
hindlimb stylopod muscle	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TTR	185	broad	marker	choroid plexus epithelium, type B pancreatic cell, right lobe of liver
IDH2	292	ubiquitous	marker	apex of heart, gastrocnemius, hindlimb stylopod muscle

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
IDH2	4,912
TTR	4,528

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TTR	P02766	462
IDH2	P48735	11

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective visual phototransduction due to STRA6 loss of function	1	1903.3×	0.005	TTR
Maturation of TCA enzymes and regulation of TCA cycle	1	285.5×	0.012	IDH2
The canonical retinoid cycle in rods (twilight vision)	1	259.6×	0.012	TTR
Citric acid cycle (TCA cycle)	1	211.5×	0.012	IDH2
Retinoid metabolism and transport	1	124.1×	0.016	TTR
Transcriptional activation of mitochondrial biogenesis	1	102.0×	0.016	IDH2
Non-integrin membrane-ECM interactions	1	77.2×	0.018	TTR
Mitochondrial protein degradation	1	57.1×	0.021	IDH2
Amyloid fiber formation	1	51.4×	0.021	TTR
Neutrophil degranulation	1	11.5×	0.085	TTR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
glyoxylate cycle	1	4213.0×	0.001	IDH2
negative regulation of glial cell migration	1	4213.0×	0.001	IDH2
negative regulation of matrix metallopeptidase secretion	1	4213.0×	0.001	IDH2
negative regulation of glomerular filtration	1	2106.5×	0.002	TTR
isocitrate metabolic process	1	1685.2×	0.002	IDH2
purine nucleobase metabolic process	1	1203.7×	0.002	TTR
NADP+ biosynthetic process	1	1203.7×	0.002	IDH2
negative regulation of glial cell proliferation	1	842.6×	0.002	IDH2
NADP+ metabolic process	1	766.0×	0.002	IDH2
phototransduction, visible light	1	648.1×	0.002	TTR
2-oxoglutarate metabolic process	1	468.1×	0.003	IDH2
tricarboxylic acid cycle	1	255.3×	0.004	IDH2
retinoid metabolic process	1	247.8×	0.004	TTR
carbohydrate metabolic process	1	68.0×	0.015	IDH2

Therapeutics

Drugs indicated for this disease

8 approved, 27 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aspirin	Approved (phase 4)
Enoxaparin Sodium	Approved (phase 4)
Eptifibatide	Approved (phase 4)
Ramipril	Approved (phase 4)
Simvastatin	Approved (phase 4)
Tenecteplase	Approved (phase 4)
Ticagrelor	Approved (phase 4)
Valsartan	Approved (phase 4)
Abciximab	Phase 3 (in late-stage trials)
Acetylcysteine	Phase 3 (in late-stage trials)
Adenosine	Phase 3 (in late-stage trials)
Anakinra	Phase 3 (in late-stage trials)
Bivalirudin	Phase 3 (in late-stage trials)
Clopidogrel	Phase 3 (in late-stage trials)
Cyclosporine	Phase 3 (in late-stage trials)
Darbepoetin Alfa	Phase 3 (in late-stage trials)
Empagliflozin	Phase 3 (in late-stage trials)
Epoetin Beta	Phase 3 (in late-stage trials)
Exenatide	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Furosemide	Phase 3 (in late-stage trials)
Heparin	Phase 3 (in late-stage trials)
Human Immunoglobulin G	Phase 3 (in late-stage trials)
Insulin Glargine	Phase 3 (in late-stage trials)
Insulin Glulisine	Phase 3 (in late-stage trials)
Insulin Human	Phase 3 (in late-stage trials)
Metoprolol	Phase 3 (in late-stage trials)
Morphine	Phase 3 (in late-stage trials)
Pexelizumab	Phase 3 (in late-stage trials)
Sacubitril	Phase 3 (in late-stage trials)
Selatogrel	Phase 3 (in late-stage trials)
Sitagliptin	Phase 3 (in late-stage trials)
Sodium Chloride	Phase 3 (in late-stage trials)
Streptokinase	Phase 3 (in late-stage trials)
Tirofiban	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Edoxaban, Ethylene, Gelatin, Inosine, Lenograstim, Melatonin, Nesiritide, Nitric Oxide, Oxygen, Rosuvastatin, Sevoflurane, Sodium Iodide, Thymosin.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TTR	TRICLABENDAZOLE
IDH2	ENASIDENIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TTR	29	4
IDH2	7	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
TRICLABENDAZOLE	4	TTR
AMLEXANOX	4	TTR
TOLCAPONE	4	TTR
DICLOFENAC	4	TTR
LEVOTHYROXINE	4	TTR
TAFAMIDIS	4	TTR
BENZIODARONE	4	TTR
BITHIONOL	4	TTR
BENZBROMARONE	4	TTR
ACORAMIDIS	4	TTR
GEMFIBROZIL	4	TTR
MECLOFENAMIC ACID	4	TTR
DASATINIB	4	TTR
DEXTROTHYROXINE	4	TTR
TRICLOSAN	4	TTR
DIFLUNISAL	4	TTR
ENASIDENIB	4	IDH2
ENASIDENIB MESYLATE	4	IDH2
IVOSIDENIB	4	IDH2
VORASIDENIB	4	IDH2
OLUTASIDENIB	4	IDH2
CAFFEIC ACID	3	TTR
RESVERATROL	3	TTR
EPIGALOCATECHIN GALLATE	3	TTR
DIACEREIN	3	TTR
TOLFENAMIC ACID	2	TTR
LUTEOLIN	2	TTR
FLUFENAMIC ACID	2	TTR
XANTHOHUMOL	2	TTR
GENISTEIN	2	TTR

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TTR	423	Binding:391, Functional:32
IDH2	84	Binding:84

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
IDH2	1.1.1.42	isocitrate dehydrogenase (NADP+)

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TTR	423

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
TRICLABENDAZOLE	4	TTR
AMLEXANOX	4	TTR
TOLCAPONE	4	TTR
DICLOFENAC	4	TTR
LEVOTHYROXINE	4	TTR
TAFAMIDIS	4	TTR
BENZIODARONE	4	TTR
BITHIONOL	4	TTR
BENZBROMARONE	4	TTR
ACORAMIDIS	4	TTR
GEMFIBROZIL	4	TTR
MECLOFENAMIC ACID	4	TTR
DASATINIB	4	TTR
DEXTROTHYROXINE	4	TTR
TRICLOSAN	4	TTR
DIFLUNISAL	4	TTR
ENASIDENIB	4	IDH2
ENASIDENIB MESYLATE	4	IDH2
IVOSIDENIB	4	IDH2
VORASIDENIB	4	IDH2
OLUTASIDENIB	4	IDH2
CAFFEIC ACID	3	TTR
RESVERATROL	3	TTR
EPIGALOCATECHIN GALLATE	3	TTR
DIACEREIN	3	TTR
TOLFENAMIC ACID	2	TTR
LUTEOLIN	2	TTR
FLUFENAMIC ACID	2	TTR
XANTHOHUMOL	2	TTR
GENISTEIN	2	TTR

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	TTR, IDH2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 608.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	401
PHASE4	81
PHASE2	49
PHASE3	36
PHASE2/PHASE3	15
PHASE1/PHASE2	13
PHASE1	13

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02739711	PHASE4	ACTIVE_NOT_RECRUITING	Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow
NCT03462498	PHASE4	ACTIVE_NOT_RECRUITING	ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
NCT03646357	PHASE4	ACTIVE_NOT_RECRUITING	BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
NCT03778554	PHASE4	ACTIVE_NOT_RECRUITING	Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
NCT04654052	PHASE4	ACTIVE_NOT_RECRUITING	VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
NCT04755387	PHASE4	RECRUITING	Ticagrelor De-escalation Strategy in AMI Patients
NCT04899479	PHASE4	RECRUITING	Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
NCT05292404	PHASE4	RECRUITING	Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
NCT05466968	PHASE4	NOT_YET_RECRUITING	Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
NCT05527717	PHASE4	RECRUITING	Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
NCT05631769	PHASE4	ACTIVE_NOT_RECRUITING	HOST - DAPT Duration According the Bleeding Risk
NCT06336317	PHASE4	RECRUITING	Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE
NCT06515730	PHASE4	RECRUITING	Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
NCT06557811	PHASE4	NOT_YET_RECRUITING	Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
NCT06683131	PHASE4	NOT_YET_RECRUITING	Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06710184	PHASE4	RECRUITING	Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction
NCT06812546	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
NCT07153744	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
NCT07467213	PHASE4	NOT_YET_RECRUITING	Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction
NCT07536802	PHASE4	RECRUITING	Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
NCT00157768	PHASE4	COMPLETED	IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction
NCT00178620	PHASE4	COMPLETED	Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
NCT00191282	PHASE4	COMPLETED	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00222573	PHASE4	COMPLETED	Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
NCT00257153	PHASE4	COMPLETED	Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction.
NCT00257309	PHASE4	TERMINATED	Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients
NCT00288665	PHASE4	COMPLETED	Thrombectomy and Improvement of Left Ventricular Function in AMI
NCT00300833	PHASE4	UNKNOWN	Treating Acute MI Patients With Aggrastat on Their Way to Hospital
NCT00302419	PHASE4	COMPLETED	Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction
NCT00362778	PHASE4	COMPLETED	Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia
NCT00383136	PHASE4	COMPLETED	FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab
NCT00423020	PHASE4	UNKNOWN	Anti-Restenosis After AMI by Erythropoietin
NCT00536887	PHASE4	COMPLETED	Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction
NCT00538317	PHASE4	COMPLETED	GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction
NCT00611169	PHASE4	COMPLETED	The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction
NCT00627809	PHASE4	COMPLETED	Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction
NCT00683111	PHASE4	COMPLETED	Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease
NCT00688922	PHASE4	UNKNOWN	Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study
NCT00692718	PHASE4	UNKNOWN	N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
NCT00712894	PHASE4	COMPLETED	Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLOPIDOGREL	4	9
BISOPROLOL	4	6
METOPROLOL	4	6
ABCIXIMAB	4	4
ATORVASTATIN	4	3
BIVALIRUDIN	4	3
CANGRELOR	4	3
DILTIAZEM	4	3
TICAGRELOR	4	3
TIROFIBAN	4	3
ACETYLCYSTEINE	4	2
ADENOSINE	4	2
ANAKINRA	4	2
HEPARIN	4	2
INSULIN HUMAN	4	2
MELATONIN	4	2
NICORANDIL	4	2
NITRIC OXIDE	4	2
RETEPLASE	4	2
SODIUM IODIDE	4	2
STREPTOKINASE	4	2
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	4	1
ALIROCUMAB	4	1
APIXABAN	4	1
ASPIRIN	4	1
CARVEDILOL	4	1
COLCHICINE	4	1
CYANOCOBALAMIN	4	1
DEXRAZOXANE	4	1
DEXRAZOXANE HYDROCHLORIDE	4	1